Key facts
- It has raised $400.2M across 3 recorded rounds; the latest was PIPE ($400.2M) in Mar 2024.
- 5 institutional filers report fund marks on Avidity Biosciences across 26 filings.
- Avidity Biosciences has filed 3 Form Ds with the SEC since 2017, most recently Mar 2024 ($400.2M sold to 45 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Avidity Biosciences
Create free account
No card required
Funding rounds
3 roundsAbout Avidity Biosciences
- Industry
- Drug Discovery
PA Mark — not yet priced
Avidity Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Avidity Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
5 filers · latest Nov 20255 SEC-registered funds reported 26 fair-value marks on Avidity Biosciences between Apr 2025 and Nov 2025. Filer-level marks and implied $/share are available to Pro members.